Hypogonadism and Obesity

[1]  M. Carini,et al.  Tadalafil effect on metabolic syndrome-associated bladder alterations: an experimental study in a rabbit model. , 2014, The journal of sexual medicine.

[2]  E. Mannucci,et al.  Erectile dysfunction and central obesity: an Italian perspective , 2014, Asian journal of andrology.

[3]  E. Sarchielli,et al.  Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: An experimental study in the rabbit , 2014, Molecular and Cellular Endocrinology.

[4]  E. Sarchielli,et al.  Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits , 2014, Molecular and Cellular Endocrinology.

[5]  E. Sarchielli,et al.  Negative Effects of High Glucose Exposure in Human Gonadotropin-Releasing Hormone Neurons , 2013, International journal of endocrinology.

[6]  K. Westerterp,et al.  Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia. , 2013, European journal of endocrinology.

[7]  A. Traish,et al.  Long‐term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss , 2013, Obesity.

[8]  L. Vignozzi,et al.  Risks and Benefits of Late Onset Hypogonadism Treatment: An Expert Opinion , 2013, The world journal of men's health.

[9]  M. Maggi,et al.  Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[10]  G. Forti,et al.  Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. , 2013, European journal of endocrinology.

[11]  D. Goulis,et al.  The complex interaction between obesity, metabolic syndrome and reproductive axis: a narrative review. , 2013, Metabolism: clinical and experimental.

[12]  G. Forti,et al.  The identification of prediabetes condition with ARIC algorithm predicts long-term CV events in patients with erectile dysfunction. , 2013, The journal of sexual medicine.

[13]  A. Lenzi,et al.  Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome‐associated prostate alterations: An experimental study in the rabbit , 2013, The Prostate.

[14]  S. Boonen,et al.  Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. , 2013, European journal of endocrinology.

[15]  L. Gooren,et al.  IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. , 2013, The journal of sexual medicine.

[16]  M. Carini,et al.  Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  M. Tena-Sempere,et al.  Kisspeptins and reproduction: physiological roles and regulatory mechanisms. , 2012, Physiological reviews.

[18]  G. Balercia,et al.  Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. , 2012, The journal of sexual medicine.

[19]  L. Vignozzi,et al.  Emerging medication for the treatment of male hypogonadism , 2012, Expert opinion on emerging drugs.

[20]  M. Carini,et al.  Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. , 2012, The Journal of endocrinology.

[21]  A. Isidori,et al.  Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review , 2012, Current diabetes reviews.

[22]  E. Mannucci,et al.  How to recognize late-onset hypogonadism in men with sexual dysfunction. , 2012, Asian journal of andrology.

[23]  A. Herbison,et al.  Gonadotropin-releasing hormone neurons extend complex highly branched dendritic trees outside the blood-brain barrier. , 2011, Endocrinology.

[24]  A. Lenzi,et al.  Testosterone and metabolic syndrome: a meta-analysis study. , 2011, The journal of sexual medicine.

[25]  A. Lenzi,et al.  Type 2 diabetes mellitus and testosterone: a meta-analysis study. , 2011, International journal of andrology.

[26]  G. Forti,et al.  Update in testosterone therapy for men. , 2011, The journal of sexual medicine.

[27]  Gretchen A. Stevens,et al.  National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants , 2011, The Lancet.

[28]  J. George,et al.  Hypothesis: Kisspeptin Mediates Male Hypogonadism in Obesity and Type 2 Diabetes , 2010, Neuroendocrinology.

[29]  E. Sarchielli,et al.  Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. , 2009, The journal of sexual medicine.

[30]  G. Vannelli,et al.  Dihydrotestosterone and leptin regulate gonadotropin-releasing hormone (GnRH) expression and secretion in human GnRH-secreting neuroblasts. , 2009, The journal of sexual medicine.

[31]  G. Balercia,et al.  Low levels of androgens in men with erectile dysfunction and obesity. , 2008, The journal of sexual medicine.

[32]  A. Silman,et al.  Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. , 2008, The Journal of clinical endocrinology and metabolism.

[33]  G. Forti,et al.  Which patients with sexual dysfunction are suitable for testosterone replacement therapy? , 2007, Journal of endocrinological investigation.

[34]  G. Vannelli,et al.  Sex steroids and leptin regulate the "first Kiss" (KiSS 1/G-protein-coupled receptor 54 system) in human gonadotropin-releasing-hormone-secreting neuroblasts. , 2005, The journal of sexual medicine.

[35]  M. Serio,et al.  Expression and biological effects of endothelin-1 in human gonadotropin-releasing hormone-secreting neurons. , 2000, The Journal of clinical endocrinology and metabolism.

[36]  A. Becchetti,et al.  Neuroblast long-term cell cultures from human fetal olfactory epithelium respond to odors , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[37]  J. Kaufman,et al.  Pathogenesis of the decreased androgen levels in obese men. , 1994, The Journal of clinical endocrinology and metabolism.

[38]  J. Kaufman,et al.  Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. , 1993, The Journal of clinical endocrinology and metabolism.

[39]  W. Rosner,et al.  Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. , 1990, The Journal of clinical endocrinology and metabolism.

[40]  M. Maggi,et al.  Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. , 2013, The journal of sexual medicine.

[41]  Mario Maggi,et al.  Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. , 2011, The journal of sexual medicine.

[42]  G. Balercia,et al.  Pulse pressure, an index of arterial stiffness, is associated with androgen deficiency and impaired penile blood flow in men with ED. , 2009, The journal of sexual medicine.